Track topics on Twitter Track topics that are important to you
ALPHARETTA, Ga., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage clinical biopharmaceutical company developing first-in-class drug therapies to treat blinding diseases of the eye, today announced that results from their Phase 2 clinical trial (DOGWOOD) and Phase 1/2 clinical trial for the treatment of macular edema associated with non-infectious uveitis will be presented at the 2016 Annual Meeting of the American Society of Retina Specialists (ASRS), August 9-14, 2016, in San Francisco, CA.
Steven Yeh, MD, Louise M. Simpson Professor of Ophthalmology and Uveitis and Vitreoretinal Surgery Director, Uveitis and Vasculitis Service at the Emory Eye Center, Emory University, will present:
Seenu Hariprasad, MD, Shui-Chin Lee Professor of Ophthalmology and Visual Science, Chief, Vitreoretinal Service and Director of Clinical Research at the University of Chicago Department of Ophthalmology and Visual Science, will present:
Shree K. Kurup, MD, Retina Center Tucson (AZ), former Professor, Director Medical Retina and Vitreoretinal Surgery and Research at the Kansas University Eye Center, University of Kansas and former Associate Professor, Surgical Sciences, Bowman Gray School of Medicine at Wake Forest University, will present:
About Clearside Biomedical, Inc.
Clearside Biomedical, Inc., headquartered in Alpharetta, GA, is a publicly-traded, late-stage clinical biopharmaceutical company developing innovative first-in-class drug therapies to treat blinding diseases of the eye using Clearside’s proprietary suprachoroidal space microinjector to reach diseased tissue through the suprachoroidal space. Clearside holds intellectual property protecting the delivery of drugs of any type through the suprachoroidal space to reach the back of the eye. Clearside has a portfolio of clinical and pre-clinical programs using drug administration through the suprachoroidal space to provide a route of access to treat diseases of the back-of-the-eye such as retinal vein occlusion (RVO), uveitis, neovascular age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Clearside is currently enrolling patients in a Phase 3 clinical trial (PEACHTREE) for the treatment of patients with macular edema associated with non-infectious uveitis and has initiated IND-enabling studies for the treatment of wet AMD. Visit www.clearsidebio.com for more information.
Contacts Company: Charles Deignan Chief Financial Officer 678-270-4005 firstname.lastname@example.org Investors: Matthew Beck The Trout Group 646-378-2933 email@example.comNEXT ARTICLE
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...